In NSCLC, would you manage other MET alterations, such as a MET T618T mutation, in the same way as a MET exon 14 skipping mutation?  

It depends on the specific MET alteration. For example, nonsynonymous SNV mutations in the juxtamembrane region that affect the Cbl binding site, such as Y1003F, may exhibit oncogenic potential similar to exon 14 skipping mutations. However, synonymous mutations such as the one in question, T618T, m...